PRNewsWire
14 Mar 2026, 01:57 UTC · 31w ago
Verdict
Headline leans bearish. We score QURE −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
uniQure disclosed that the FDA no longer agrees that Phase I/II data for AMT-130 may be adequate to support a BLA submission, making the BLA timing unclear.
More negative than 99% of claims this week
Following the FDA disclosure, uniQure's stock price plummeted more than 49%, falling from $67.69 to $34.29 per share.
So whatA nearly 50% instantaneous destruction of market capitalization confirms massive negative revaluation by investors due to the regulatory setback.
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 99% of claims this week
A securities class action lawsuit has been filed against uniQure alleging the company failed to disclose material information during the class period.
So whatSecurities litigation introduces financial uncertainty, potential settlement costs, and management distraction, though the primary valuation impact was already driven by the drug's regulatory delay.
More negative than 84% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a securities fraud class action lawsuit following a 49% stock decline and FDA approval delays for its lead drug candidate.
More negative than 72% of ticker scores this week
The company is the subject of an investigation by a securities litigation law firm regarding its officers and directors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
+44.6%
Price is moving against the score
$22.45 vs $15.53 close before publication (Mar 13) · not market-adjusted
QURE chart →
